目的 探讨甲状腺髓样癌合并乳头状癌患者的临床特征、病理特点、诊疗情况。方法 回顾性分析1例甲状腺髓样癌合并乳头状癌患者的临床表现、检验检查及病理学结果,并复习相关文献。结果 患者女性,56岁,因双侧甲状腺结节收入院,术前检测降钙素：>2000.0 pg/mL,CEA：132.0 ng/mL,pro-GPR：440.0 ng/mL,怀疑髓样癌可能;术中冰冻病理提示：左侧甲状腺乳头状癌,右侧髓样癌可能;于全麻下行甲状腺全切和双侧颈部中央组淋巴结清扫术,术后病理结果诊断：左侧甲状腺乳头状癌,右侧甲状腺髓样癌。结论 甲状腺髓样癌合并乳头状癌临床上比较罕见,本文通过病例分析和文献复习,为该类病人的诊疗提供借鉴。
Objective To investigate the clinicopathological features, diagnosis, and treatment of medullary thyroid carcinoma （MTC） complicated with papillary thyroid carcinoma （PTC）. Methods A retrospective analysis was conducted of a case of MTC and PTC and related literature was reviewed. Results A female patient was admitted to the hospital due to bilateral thyroid nodules. Preoperative calcitonin： >2000.0 pg/mL, CEA： 132.0 ng/mL, pro-GPR： 440.0 ng/mL. Preoperative diagnosis： medullary carcinoma? Intraoperative frozen pathology suggested PTC on the left and MTC on the right. Total thyroidectomy with bilateral central lymph node dissection was performed. Postoperative pathological results revealed right MTC and left PTC. Conclusion Synchronous occurrence of MTC and PTC in a patient is rare. This case report and literature review provide references for the diagnosis and treatment of such patients.
[1] Nabhan F, Dedhia PH, Ringel MD.Thyroid cancer, recent advances in diagnosis and therapy[J]. Int J Cancer, 2021, 149(5): 984-992.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[3] Kim M, Kim BH.Current guidelines for management of medullary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2021, 36(3): 514-524.
[4] Kim WG, Gong G, Kim EY, et al.Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental[J]. Clin Endocrinol (Oxf), 2010, 72(2): 256-263.
[5] Fibbi B, Pinzani P, Salvianti F, et al.Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature[J]. Endocr Pathol, 2014, 25(3): 324-331.
[6] Jaber T, Dadu R, Hu MI.Medullary thyroid carcinoma[J]. Curr Opin Endocrinol Diabetes Obes, 2021, 28(5): 540-546.
[7] Thomas CM, Asa SL, Ezzat S, et al.Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5): 338-344.
[8] Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[9] Treglia G, Aktolun C, Chiti A, et al.The 2015 revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine[J]. Eur J Nucl Med Mol Imaging, 2016, 43(8): 1486-1490.
[10] Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6): 567-610.
[11] Maia AL, Siqueira DR, Kulcsar MA, et al.Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism[J]. Arq Bras Endocrinol Metabol, 2014, 58(7): 667-700.
[12] Hu MI, Waguespack SG, Dosiou C, et al.Afirma genomic sequencing classifier and xpression atlas molecular findings in consecutive bethesda III-VI thyroid nodules[J]. J Clin Endocrinol Metab, 2021, 106(8): 2198-2207.
[13] 沈雷, 曹慧敏, 李苑. 基于分子生物学的甲状腺癌诊疗进展[J]. 外科研究与新技术, 2015, 4(3): 196-200.
[14] 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, et al. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012, 28(10): 779-797.
[15] Li J, Chen Y, Wang X, et al.The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer[J]. Transl Cancer Res, 2021, 10(4): 1900-1906.
[16] Yamaguchi K, Katagiri H, Takahashi M, et al.ProGRP is a possible tumor marker for patients with Ewing sarcoma[J]. Biomed Res, 2015, 36(4): 273-277.
[17] Parra-Robert M, Orois A, Augé JM, et al.Utility of proGRP as a tumor marker in the medullary thyroid carcinoma[J]. Clin Chem Lab Med, 2017, 55(3): 441-446.
[18] Ma SH, Liu QJ, Zhang YC, et al.Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma: Long-term follow-up[J]. Oncol Lett, 2011, 2(5): 975-980.
[19] Fan W, Xiao C, Wu F.Analysis of risk factors for cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma[J]. J Int Med Res, 2018, 46(5): 1982-1989.
[20] Machens A, Dralle H.Biomarker-based risk stratification for previously untreated medullary thyroid cancer[J]. J Clin Endocrinol Metab, 2010, 95(6): 2655-2663.
[21] Jayasinghe R, Basnayake O, Jayarajah U, et al.Management of medullary carcinoma of the thyroid: a review[J]. J Int Med Res, 2022, 50(7): 1-20.
[22] Pena I, Clayman GL, Grubbs EG, et al.Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer[J]. Head Neck, 2018, 40(1): 79-85.
